DUBLIN, May 7, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that The Allergan Foundation has fast-tracked another $2 million dollars in charitable grants for community organizations responding to the COVID-19 pandemic. The new grants double The Allergan Foundation's total COVID-19 donations to date, raising the total to $4 million. The donations are dedicated to 57 organizations working on the front lines of the community response to the pandemic in New York, New Jersey, California, Texas, Ohio, Florida and internationally.

DUBLIN, May 6, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) ("Allergan") today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Allergan by AbbVie Inc. ("AbbVie") by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act").

DUBLIN, April 28, 2020 /PRNewswire/ --  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION Allergan plc (NYSE: AGN) ("Allergan") announced today that it has notified the New York Stock Exchange ("NYSE") of its intention to voluntarily withdraw from listing on the NYSE and from registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") any and all outstanding notes and related guarantees of the following series issued by Allergan Funding SCS, a subsidiary of Allergan: (i) Floating Rate Notes due 2020 (NYSE: AGN20A), (ii) 0.500% Senior Notes due 2021 (NYSE: AGN21), (iii) 1.500% Senior Notes due 2023 (NYSE: AGN23A), (iv) 1.250% Senior Notes due 2024 (NYSE: AGN24A), (v) 2.625% Senior Notes due 2028 (NYSE: AGN28) and (vi) 2.125% Senior Notes due 2029 (NYSE: AGN29) (clauses (i)-(vi) collectively, the "Allergan Funding SCS Notes") in each case, following the consummation of the previously announced proposed acquisition (the "Transaction") of Allergan by AbbVie Inc. ("AbbVie") by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014. The proposed delisting of the Allergan Funding SCS Notes and related guarantees is contingent upon the closing of the Transaction, which is subject to, among other conditions, the receipt of necessary regulatory approvals. To effect the delisting, Allergan expects Allergan Funding SCS and each guarantor of the Allergan Funding SCS Notes to file a Form 25 in respect of the Allergan Funding SCS Notes with the Securities and Exchange Commission. Allergan reserves the right to delay the filing of the Form 25 or to withdraw such filing for any reason prior to its effectiveness, including, without limitation, in the event that the Transaction is delayed or is not completed for any reason.

-- XEN^® Becomes the First Medical Product Approved by Using Real World Evidence in China -- DUBLIN, April 2, 2020 /CNW/ -- Allergan plc (NYSE: AGN) today announced China's National Medical Products Administration (NMPA) approved the registration of Allergan's XEN^® Gel Stent on March 26, 2020 for the surgical management of patients with refractory glaucoma.  XEN^® is the first product to be approved in China through the Real World Evidence pathway.

DUBLIN, March 31, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it has received the ENERGY STAR^® Partner of the Year Sustained Excellence Award for 2020, marking the seventh consecutive year it has earned ENERGY STAR^®'s highest honor. The U.S. Environmental Protection Agency award recognizes Allergan for its continued leadership in energy management and efficiency.

DUBLIN, March 30, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that The Allergan Foundation has awarded approximately $13 million in charitable grants in 2020 as part of its commitment to providing a lasting and positive impact in the communities in which Allergan employees live and work. The 2020 donations support programs dedicated to the COVID-19 pandemic response as well as initiatives supporting Mental Health, Eye Care and Breast Health. The 2020 grants bring The Allergan Foundation's total donations in its 22-year history to approximately $108 million, including $57 million since the beginning of 2015.

DUBLIN, March 18, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the second quarter of 2020. The dividend will be paid on the closing date of AbbVie's pending acquisition of Allergan, which remains subject to regulatory approval and customary closing conditions, or on June 15, 2020 if closing has not yet occurred. Allergan's second quarter 2020 dividend will be paid to shareholders of record at the close of business on April 16, 2020.

DUBLIN, March 10, 2020 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (NYSE: AGN) ("Allergan") confirms that, as of the close of business on March 6, 2020, Allergan's issued share capital, excluding treasury shares, consisted of 329,172,167 ordinary shares, par value US$0.0001 per share (the "Allergan Ordinary Shares"). The International Securities Identification Number (ISIN) of the Allergan Ordinary Shares is IE00BY9D5467.

DUBLIN, March 5, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's New Drug Application (NDA) for DURYSTA™ (bimatoprost implant) 10 mcg for intracameral administration. With this approval, DURYSTA™ becomes the first intracameral, biodegradable sustained-release implant indicated to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).